Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details) - USD ($) $ in Millions	12 Months Ended
Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Reimbursement of research and development expenses \| Teva
Disaggregation of Revenue [Line Items]
Reduction of Research and development expense	$ 109.4	$ 122.9	$ 129.5
Amounts recognized in connection with up-front and development milestone payments received
Disaggregation of Revenue [Line Items]
Other operating income	$ 47.2	$ 82.2	$ 113.2

The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Name:	us-gaap_OtherOperatingIncome
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration